Skip to content
GLP-1 Scorecard
Menu
Graded #149

Kin Meds

Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and pill, Zepbound and Foundayo from $149/mo.

Visit Kin MedsWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$149/mo (brand Wegovy)
Tirzepatide
$149/mo (brand Zepbound)
Coverage
Coverage not published
Brand-name
Yes

Weigh Kin Meds against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value74/100
Dose & formulation93/100
Clinical oversight55/100
Labs & monitoring53/100
Fulfillment72/100
Contract terms55/100

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database

Bottom line — Grade C

Best for: Shoppers who want compounded and brand-name GLP-1 plus a longevity stack on one platform.

Ranked #149 of 544 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.

Closest here

The rankings grading nearest Kin Meds — the realistic shortlist.

The 21 rankings nearest this one

View full scorecard rankings →

Pricing/verification reflect Kin Meds's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Kin Meds's site. Not medical advice; see our disclosure.

← Back to the scorecard